BMS-986504 NSCLC Treatment Durable Response

Here’s a summary of the key ‍facts from the provided text⁢ regarding BMS-986504:

What ⁢it is: BMS-986504 is being investigated as a cancer treatment.
Study Details: A Phase⁢ I study evaluated the drug⁣ in ‍patients with advanced solid tumors.
Follow-up: Median follow-up was 11.7‍ months (range ⁤4.2-12.4 ⁢months).
Safety/Tolerability: ⁢ The drug was well-tolerated. Most side effects were mild⁢ (Grade 1 or 2). 14% of solid‍ tumor patients experienced more serious side effects (Grade ⁤≥3).
Side Effects: Low rates of hematologic toxicity were observed:
‍
Anemia: 8%
Neutropenia: 7%
⁣
⁢ Thrombocytopenia: 7%
Tumor Types: The study included patients with NSCLC, mesothelioma, pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma.No new safety signals were seen across⁣ these types.
Future Studies: Two further studies are planned specifically for patients with advanced NSCLC and a specific genetic mutation (MTAP deletion):
NCT06855771: Phase II study ⁤of⁤ BMS-986504 ‍alone.
⁤
NCT07063745: Phase II/III study of BMS-986504 combined ⁤with pembrolizumab and chemotherapy.